|Videos|May 8, 2023

Clinical Considerations in the Treatment of Alopecia Areata

Author(s)Neil Minkoff, MD, Natasha Mesinkovska, MD , Brett King, MD, PhD

Neil Minkoff; Natasha Mesinkovska, MD; and Brett King, MD, PhD discuss the diagnosis and disease assessment in alopecia areata along with clinical considerations.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Health System Best Practices for JOURNAVX® (suzetrigine) Adoption

June 2nd 2026

Bone Health in Oncology: Closing Gaps, Reducing Costs, and Unlocking Biosimilar Value

March 30th 2026

Postmenopausal Osteoporosis: Clinical Burden, Treatment Barriers, and the Evolving Role of Denosumab Biosimilars

February 18th 2026

Advancing Osteoporosis Care in Canada: Insights on Biosimilars and Patient-Centered Switching

January 16th 2026

How Clinician-Led Partnerships Strengthen Post-Acute Care

ByAmy Harris, AVP of Value-Based Operations, OneHome

September 25th 2025

Clinical Considerations in the Treatment of Alopecia Areata

Related Content

Health System Best Practices for JOURNAVX® (suzetrigine) Adoption

Bone Health in Oncology: Closing Gaps, Reducing Costs, and Unlocking Biosimilar Value

Postmenopausal Osteoporosis: Clinical Burden, Treatment Barriers, and the Evolving Role of Denosumab Biosimilars

Advancing Osteoporosis Care in Canada: Insights on Biosimilars and Patient-Centered Switching

How Clinician-Led Partnerships Strengthen Post-Acute Care

Trending on AJMC

Hans Lee, MD, Discusses “Off-the-Shelf” Solution for Rare Blood Disorder With No Approved Therapies

AI Billing, GLP-1s Among Forces Driving 9% Health Cost Spike

United Therapeutics Plans FDA Submission for Inhaled Treprostinil in IPF

HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD

FDA Approves Another OTC Naloxone Nasal Spray for Opioid Overdose